REGENXBIO Inc. has announced a strategic royalty monetization agreement with Healthcare Royalty (HCRx) valued at up to $250 million. The agreement involves a non-dilutive, limited recourse royalty bond, allowing REGENXBIO to monetize select anticipated royalties and milestones. The company received an immediate $150 million at closing, extending its cash runway into early 2027. This financing will support REGENXBIO's commercial preparations and late-stage activities, while also retaining potential future non-dilutive funding opportunities. The deal underlines REGENXBIO's position as a leader in rare and retinal gene therapies, aiming to unlock significant value for shareholders.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。